These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38405208)

  • 21. Efficacy and safety of pralsetinib in patients with advanced RET fusion-positive non-small cell lung cancer.
    Zhou Q; Zhao J; Chang J; Wang H; Fan Y; Wang K; Wu G; Nian W; Sun Y; Sun M; Wang X; Shi H; Zheng X; Yao S; Qin M; Shen Z; Yang J; Wu YL
    Cancer; 2023 Oct; 129(20):3239-3251. PubMed ID: 37282666
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The efficacy and safety of selective RET inhibitors in RET fusion-positive non-small cell lung cancer: a meta-analysis.
    Ke JY; Huang S; Jing ZT; Duan MC
    Invest New Drugs; 2023 Oct; 41(5):768-776. PubMed ID: 37603207
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical evidence and adverse event management update of patients with RET- rearranged advanced non-small-cell lung cancer (NSCLC) treated with pralsetinib.
    Russo GL; Bironzo P; Bennati C; Bonanno L; Catino A; Metro G; Petrini I; Russano M; Passaro A
    Crit Rev Oncol Hematol; 2024 Feb; 194():104243. PubMed ID: 38135019
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pralsetinib for RET Fusion-Positive Advanced Non-small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Al Khayat MNMT; Armstrong N; Howick J; O'Meara S; Posadzki P; Ryder S; Ahmadu C; Konings SRA; Postma MJ; Duffy S; Wolff RF; van Asselt ADI
    Pharmacoeconomics; 2023 Apr; 41(4):353-361. PubMed ID: 36757608
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enhanced antitumor effect of alectinib in combination with cyclin-dependent kinase 4/6 inhibitor against
    Fujimura T; Furugaki K; Harada N; Yoshimura Y
    Cancer Biol Ther; 2020 Sep; 21(9):863-870. PubMed ID: 32835580
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patient-reported outcomes following selpercatinib treatment in Chinese patients with advanced
    Lu S; Zheng X; Sun Y; Huang D; Wu L; Ji Q; Zhou C; Zhou J; Guo Y; Ge M; Ding D; Shao J; Zhang W; Gao M; Cheng Y
    Ther Adv Med Oncol; 2023; 15():17588359231189429. PubMed ID: 37655205
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer.
    Kodama T; Tsukaguchi T; Satoh Y; Yoshida M; Watanabe Y; Kondoh O; Sakamoto H
    Mol Cancer Ther; 2014 Dec; 13(12):2910-8. PubMed ID: 25349307
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic Advances in the Management of Patients with Advanced RET Fusion-Positive Non-Small Cell Lung Cancer.
    Sun F; McCoach CE
    Curr Treat Options Oncol; 2021 Jun; 22(8):72. PubMed ID: 34165651
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program.
    Illini O; Hochmair MJ; Fabikan H; Weinlinger C; Tufman A; Swalduz A; Lamberg K; Hashemi SMS; Huemer F; Vikström A; Wermke M; Absenger G; Addeo A; Banerji S; Calles A; Clarke S; Di Maio M; Durand A; Duruisseaux M; Itchins M; Kääränien OS; Krenn F; Laack E; de Langen AJ; Mohorcic K; Pall G; Passaro A; Prager G; Rittmeyer A; Rothenstein J; Schumacher M; Wöll E; Valipour A
    Ther Adv Med Oncol; 2021; 13():17588359211019675. PubMed ID: 34178121
    [TBL] [Abstract][Full Text] [Related]  

  • 30.
    Arai S; Kita K; Tanimoto A; Takeuchi S; Fukuda K; Sato H; Yano S
    Oncotarget; 2017 Sep; 8(43):73766-73773. PubMed ID: 29088743
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comprehensive Genomic Analysis of Patients With Non-Small-Cell Lung Cancer Using Blood-Based Circulating Tumor DNA Assay: Findings From the BFAST Database of a Single Center in Taiwan.
    Wang HY; Ho CC; Lin YT; Liao WY; Chen CY; Shih JY; Yu CJ
    JCO Precis Oncol; 2024 Jan; 8():e2300314. PubMed ID: 38190582
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeted therapy of RET fusion-positive non-small cell lung cancer.
    Shen Z; Qiu B; Li L; Yang B; Li G
    Front Oncol; 2022; 12():1033484. PubMed ID: 36582799
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Selpercatinib in RET-fusion positive metastatic non-small cell lung cancer: achievements and gray areas.
    Belluomini L; Avancini A; Pasqualin L; Insolda J; Sposito M; Menis J; Tregnago D; Trestini I; Ferrara MG; Bria E; Milella M; Pilotto S
    Expert Rev Anticancer Ther; 2022 Aug; 22(8):785-794. PubMed ID: 35726802
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-world outcomes of chemoimmunotherapy and selective RET inhibitors in Chinese patients with RET fusion-positive non-small cell lung cancer.
    Wan R; Li W; Wang Z; Zhong J; Lin L; Duan J; Wang J
    Heliyon; 2024 Jan; 10(2):e24796. PubMed ID: 38304763
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Efficacy and Safety Analysis of Selpercatinib in Patients with RET Fusion-Positive Non-Small Cell Lung Cancer-Results from the Japanese Subset of a Global Phase 1/2 Study].
    Nishio M; Ohe Y; Ohashi K; Toyozawa R; Satouchi M; Sekine N; Mori J; Enatsu S; Goto K
    Gan To Kagaku Ryoho; 2022 Jun; 49(6):669-675. PubMed ID: 35799394
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biomarker guided treatment in oncogene-driven advanced non-small cell lung cancer in older adults: A Young International Society of Geriatric Oncology report.
    Christofyllakis K; Monteiro AR; Cetin O; Kos IA; Greystoke A; Luciani A
    J Geriatr Oncol; 2022 Nov; 13(8):1071-1083. PubMed ID: 35525790
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study.
    Subbiah V; Hu MI; Wirth LJ; Schuler M; Mansfield AS; Curigliano G; Brose MS; Zhu VW; Leboulleux S; Bowles DW; Baik CS; Adkins D; Keam B; Matos I; Garralda E; Gainor JF; Lopes G; Lin CC; Godbert Y; Sarker D; Miller SG; Clifford C; Zhang H; Turner CD; Taylor MH
    Lancet Diabetes Endocrinol; 2021 Aug; 9(8):491-501. PubMed ID: 34118198
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of immune checkpoint inhibitor therapy in patients with
    Bhandari NR; Hess LM; Han Y; Zhu YE; Sireci AN
    Immunotherapy; 2021 Aug; 13(11):893-904. PubMed ID: 34139897
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selpercatinib monotherapy in a Chinese patient with RET fusion/ EGFR co-mutated nonsmall cell lung cancer from the Phase II LIBRETTO-321 study: a case report.
    Wu L; Cheng Y; Huang D; Sun Y; Zhou C; Zhou J; Guo Y; Shao J; Zhang W; Lu S
    Anticancer Drugs; 2023 Oct; 34(9):1058-1064. PubMed ID: 37265026
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Selpercatinib for adult patients with locally advanced or metastatic RET-altered solid tumors.
    Le D; Konda B
    Expert Rev Anticancer Ther; 2023; 23(11):1117-1122. PubMed ID: 37795873
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.